Genelux Overview
Latest ROE for Genelux: -209.73% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-209.73%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GNLX is -209.73%. That is below the sector sector average of -5.72%. Investors often review this figure alongside Genelux's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GNLX currently prints -209.73% for ROE, while the sector average sits near -5.72%. That is roughly 3565.1% below the sector mean. Large gaps often invite a closer look at Genelux's growth, margins, and balance sheet.
Return on Equity shows how effectively Genelux converts resources into returns. At -209.73%, GNLX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GNLX's ROE (-209.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
